Updates are available Correction dated 2025-05-27
Click to view Correction: https://doi.org/10.1038/s41408-025-01307-8
-
Authors
Maeng, Cecilie Velsoe https://orcid.org/0000-0002-7205-9330
Rögnvaldsson, Sæmundur
Einarsson Long, Thórir https://orcid.org/0000-0003-2377-7886
Brieghel, Christian https://orcid.org/0000-0002-1816-8106
Hermansen, Emil https://orcid.org/0000-0002-1754-5336
Niemann, Carsten Utoft https://orcid.org/0000-0001-9880-5242
Grønbæk, Kirsten
Kristinsson, Sigurður Yngvi https://orcid.org/0000-0002-4964-7476
Thorsteinsdóttir, Sigrún https://orcid.org/0000-0001-5017-3530
- License Information
-
More Information
Article History
Received: 14 February 2025
Revised: 8 April 2025
Accepted: 15 April 2025
First Online: 28 April 2025
Change Date: 16 May 2025
Change Type: Update
Change Details: The original online version of this article was revised: Tab. 3 has been updated has been updated due to an incorrect formatting occurred during the correction process.
Change Date: 27 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-025-01307-8
Competing interests
: CVM has participated in a conference supported by Daiichi Sankyo. SR has received honoraria for scientific talks from Siemens Healthineers and Johnson & Johnson. TL has no conflicts of interest to declare. CB has received an honorarium from AbbVie. EH reports honoraria for lectures and educational materials from Amgen, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Sanofi, and Takeda, research cooperation with Bristol Myers Squibb, Johnson & Johnson, and Sanofi, participation in conferences supported by Bristol Myers Squibb, Pfizer, Roche, and Takeda, and advisory board consultancy to Johnson & Johnson, Sanofi, and Oncopeptides. CUN has received research funding from AbbVie, Johnson & Johnson, AstraZeneca, Novo Nordisk Foundation, Genmab, and Octapharma, and has provided consultancy for AbbVie, BeiGene, Janssen, Roche, AstraZeneca, CSL Behring, Genmab, Takeda, Octapharma, MSD, Synamics, and Lilly. KG has received research funding from Janssen. SYK reports research funding from Amgen and Celgene, and an Independent Data Monitoring Committee for Johnson & Johnson. ST has received honoraria for scientific talks from AbbVie and Thermo Fisher Scientific.
: The study was conducted under the approval of Danish Lymphoid Cancer Research (DALYCARE) protocol by the Danish National Ethics Committee (1804410) and Data Protection Agency (P-2020-561). All methods were performed in compliance with all relevant guidelines and regulations for use of Danish data, including legal exemption from informed consent as a nationwide epidemiological study.
